Equities research analysts expect BioTelemetry Inc (NASDAQ:BEAT) to post sales of $97.92 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for BioTelemetry’s earnings, with the lowest sales estimate coming in at $97.79 million and the highest estimate coming in at $98.00 million. BioTelemetry reported sales of $81.02 million in the same quarter last year, which indicates a positive year over year growth rate of 20.9%. The business is scheduled to report its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that BioTelemetry will report full-year sales of $394.21 million for the current financial year, with estimates ranging from $393.28 million to $394.75 million. For the next fiscal year, analysts anticipate that the firm will report sales of $434.53 million, with estimates ranging from $432.33 million to $438.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Wednesday, July 25th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.15. BioTelemetry had a negative net margin of 0.39% and a positive return on equity of 18.02%. The company had revenue of $101.36 million during the quarter, compared to analysts’ expectations of $95.87 million. During the same period in the prior year, the company earned $0.23 earnings per share. The business’s quarterly revenue was up 74.4% compared to the same quarter last year.

Several equities research analysts recently weighed in on BEAT shares. Benchmark increased their target price on shares of BioTelemetry from $46.00 to $54.00 and gave the company a “buy” rating in a research note on Wednesday, June 20th. Lake Street Capital increased their target price on shares of BioTelemetry from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 26th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research note on Tuesday, June 26th. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Finally, SunTrust Banks increased their target price on shares of BioTelemetry to $67.00 and gave the company a “buy” rating in a research note on Friday, August 31st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. BioTelemetry has an average rating of “Buy” and a consensus target price of $61.50.

Shares of NASDAQ BEAT traded up $3.89 during mid-day trading on Thursday, hitting $56.62. The company had a trading volume of 408,200 shares, compared to its average volume of 394,784. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.12 and a current ratio of 2.29. BioTelemetry has a 12 month low of $23.30 and a 12 month high of $66.02. The stock has a market cap of $2.11 billion, a PE ratio of 55.38, a PEG ratio of 4.26 and a beta of 1.41.

In related news, insider Fred Broadway sold 90,113 shares of the stock in a transaction dated Friday, September 28th. The shares were sold at an average price of $65.00, for a total value of $5,857,345.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kirk E. Gorman sold 625 shares of the stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $62.30, for a total transaction of $38,937.50. Following the completion of the transaction, the director now directly owns 173,940 shares of the company’s stock, valued at approximately $10,836,462. The disclosure for this sale can be found here. In the last quarter, insiders sold 429,863 shares of company stock valued at $24,367,451. 8.30% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. LPL Financial LLC raised its position in BioTelemetry by 15.1% in the first quarter. LPL Financial LLC now owns 20,884 shares of the medical research company’s stock worth $648,000 after purchasing an additional 2,739 shares in the last quarter. Castleark Management LLC acquired a new position in BioTelemetry in the second quarter worth about $13,712,000. Swiss National Bank raised its position in BioTelemetry by 5.6% in the second quarter. Swiss National Bank now owns 56,600 shares of the medical research company’s stock worth $2,547,000 after purchasing an additional 3,000 shares in the last quarter. Legal & General Group Plc raised its position in BioTelemetry by 2.9% in the first quarter. Legal & General Group Plc now owns 57,741 shares of the medical research company’s stock worth $1,778,000 after purchasing an additional 1,653 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of BioTelemetry by 10.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 163,248 shares of the medical research company’s stock worth $7,347,000 after buying an additional 15,139 shares in the last quarter. 93.82% of the stock is owned by hedge funds and other institutional investors.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Featured Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.